eldavojohn writes "Almost 6 years ago we discussed a vaccine to help people quit smoking as it entered human clinical trials. Now it looks like the finishing touches have been put on a deal that will go into effect once phase III testing of the drug now called NicVAX is completed. NicVAX was developed by Nabi Biopharmaceuticals, who have agreed to license it to GlaxoSmithKline Biologicals; it is expected to complete phase III testing successfully. Others have fallen short of this goal, in pursuit of a smoking-cessation market expected to hit $4.6 billion worldwide by 2016. Nabi has also sold an experimental vaccine for staph infections; and in 2008 we discussed news of a cocaine vaccine."